Glaukos Co. (NYSE:GKOS) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund cut its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 21.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 393,110 shares of the medical instruments supplier's stock after selling 109,908 shares during the quarter. New York State Common Retirement Fund owned about 0.78% of Glaukos worth $51,214,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Assenagon Asset Management S.A. purchased a new stake in Glaukos in the second quarter valued at about $6,832,000. Natixis acquired a new stake in Glaukos in the 1st quarter worth approximately $614,000. Vanguard Group Inc. boosted its stake in Glaukos by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier's stock worth $500,576,000 after purchasing an additional 72,159 shares in the last quarter. UniSuper Management Pty Ltd purchased a new stake in Glaukos during the 1st quarter worth approximately $913,000. Finally, Duality Advisers LP acquired a new position in Glaukos during the 1st quarter valued at approximately $3,476,000. 99.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on GKOS. Truist Financial lifted their price target on Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Piper Sandler set a $140.00 target price on Glaukos in a research report on Thursday, October 17th. Needham & Company LLC raised their price target on shares of Glaukos from $131.00 to $137.00 and gave the stock a "buy" rating in a research report on Thursday, August 1st. BTIG Research upped their price objective on shares of Glaukos from $131.00 to $139.00 and gave the company a "buy" rating in a report on Wednesday, August 28th. Finally, Citigroup cut shares of Glaukos from a "buy" rating to a "neutral" rating and raised their target price for the stock from $130.00 to $132.00 in a report on Wednesday, July 10th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $130.45.

Glaukos Price Performance

Shares of GKOS stock traded down $0.48 on Friday, reaching $131.77. 646,235 shares of the company were exchanged, compared to its average volume of 457,156. The company has a market cap of $7.24 billion, a price-to-earnings ratio of -40.42 and a beta of 1.02. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $139.51. The business has a 50-day moving average price of $129.68 and a 200 day moving average price of $119.57. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The business's revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.55) earnings per share. Equities research analysts forecast that Glaukos Co. will post -2.16 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Marc Stapley sold 6,250 shares of Glaukos stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the transaction, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,525 shares of company stock valued at $5,142,029 over the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.